clinical trial · NCT04479241
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.·phase2·completed·n = 25
GlioblastomaRecurrent GlioblastomaSupratentorial GlioblastomaBrain Tumorlerapolturevpembrolizumab
brief summary
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.
started
Oct 21, 2020
primary completion
Jun 5, 2024
completion
Jun 21, 2024
last updated
Jun 5, 2025
official title
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol